CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will present at the 2015 UBS Global Healthcare Conference on Monday, May 18, 2015, at 9:30 a.m. Eastern Time. The conference is being held at The Sheraton New York Hotel in New York City.

A live audio webcast of the presentation will be available on the company's website at http://ir.akebia.com/events.cfm. An archived presentation will be available for 90 days.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through HIF biology. Akebia's lead product candidate, AKB-6548, is a once-daily, oral therapy, which has completed a Phase 2b study for the treatment of anemia related to chronic kidney disease in non-dialysis patients and is also being tested in a Phase 2 study for the treatment of anemia in patients undergoing dialysis.

Investors:
Argot Partners
Andrea Rabney, +1-212-600-1902
Andrea@argotpartners.com
or
Media:
Argot Partners
Eliza Schleifstein, +1-917-763-8106
Eliza@argotpartners.com

Source: Akebia Therapeutics, Inc.

News Provided by Acquire Media